home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences  
 

How to Prevent or Handle Protocol Deviations and Violations to be GCP

 
  February 01, 2011  
     
 


ComplianceOnline, Online Event
2011-03-10


NOTE: Use This Promocode ( 117660 ) To Get 10% Discount.  

Why Should You Attend: Following exactly the signed and approved (IRB + PI) Protocol to the letter is the goal and mandate of all clinical research. This, in fact, is included on the FDA Form 1572.

This Webinar deals with what happens, and under what circumstances, when the protocol is not followed (PNF) and why this is of particular significance. Covered, will be how a protocol deviation with the least significant effect where there is no substantive effect on the risks to research participants, no substantial effect of the value or integrity of the data, and did not result from willful or knowing misconduct on the part of the investigator is handled.

It will be important to see what the FDA regulations and the ICH GCP recommendations are in this regard. Most importantly, when do a protocol deviation / change lead to a protocol amendment. There are differences in actions, reporting and consequences of deviations and violations and these will be discussed. The key is that the PI and all clinical staff know and follow the research plan (Protocol) exactly as it is written. To do this is ethical research. TO not follow the protocol is folly.

Areas Covered in the Seminar:

  • The Primacy of the study Protocol.
  • What are Protocol “Deviation” and other terms / categories.
  • The many cause of protocol deviations.
  • The Regulatory requirements for handling protocol deviations and violations.
  • The importance of documentation of protocol deviations as well as violations.
  • How to define and handle instances of PNF.
  • What is the reason different IRBs define deviations and violations differently.
  • What is the basis of the difference between a “Deviation” and a “Violation”.

Who Will Benefit:

This Webinar will provide invaluable assistance to the pharmaceutical industry and to investigators and their staff in the regulatory / legal responsibilities and also the ethical considerations in pharmaceutical product (Drug or device) research involving human subjects. Those benefiting the most would be:
  • Principal Investigators / Sub-investigators.
  • Clinical Research Scientists (PKs, Biostatisticians,)
  • Safety Nurses
  • Clinical Research Associates (CRAs) and Coordinators (CRCs)
  • Recruiting staff
  • QA / QC auditors and staff.
  • Clinical Research Data managers
 
 
Organized by: ComplianceOnline
Invited Speakers:
Charles H. Pierce, MD, PhD, FCP, CPI Has 20+ years experience in bringing the message (via webinars, lectures and seminars) of Risk Management through knowledge of GCP Regulations and Investigator Responsibility to the entire investigative team to help them understand the regulations as well as the ethics of research involving human subjects. He has been involved in developing Phase I & IIa Clinical Pharmacology Units, Investigator and staff GCP training, and medical monitoring in both drug and device studies.
 
Deadline for Abstracts: 2011-03-10
 
Registration:

Attend Live Online Training

$249.00 One Dial-in One Attendee

$999.00 Group–Max. 10 Attendees

(For multiple locations contact Customer Care) 

E-mail: referral@complianceonline.com
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.